研究者詳細 - 小川　靖

論文 - 小川　靖

分割表示 52 件中 1 - 20 件目／全件表示 >>

The impact of COVID-19 on hay fever treatment in Japan: A retrospective cohort study based on the Japanese claims database

Akasaki Y., Inomata T., Iwagami M., Sung J., Nagino K., Adachi T., Morita H., Tamari M., Kainuma K., Kan-o K., Ogata H., Sakashita M., Futamura M., Kurashima Y., Nakajima S., Masaki K., Ogawa Y., Sato S., Miyagawa A., Midorikawa-Inomata A., Fujimoto K., Okumura Y., Fujio K., Huang T., Hirosawa K., Morooka Y., Murakami A., Nakao S.

Clinical and Translational Allergy 14 巻 ( 9 ) 2024年9月

掲載種別：研究論文（学術雑誌）出版者・発行元：Clinical and Translational Allergy

Background: Hay fever (HF) presents with various symptoms, including allergic conjunctivitis and rhinitis, and requires cross-organ treatment. This study assessed the impact of the coronavirus disease 2019 (COVID-19) pandemic on HF treatment trends. Methods: This retrospective cohort study utilized data from the JMDC database collected between January 2018 and May 2021. Patients with HF were identified based on the relevant International Classification of Diseases 10th Revision diagnosis codes and the prescription of HF-related medications. The treatment approaches were compared during the cedar and cypress pollen allergy season (January to May in Japan) before and during the COVID-19 pandemic (2018 and 2019, and 2020 and 2021, respectively). Results: This study included 2,598,178 patients with HF. The numbers of prescribed HF-related claims in 2018, 2019, 2020, and 2021 were 3,332,854, 3,534,198, 2,774,380, and 2,786,681 times, respectively. Oral second-generation antihistamine prescriptions decreased by >10% from 2019 to 2020, with a <10% change in the subsequent year. Anti-allergic eye drop prescriptions also decreased by >10% from 2019 to 2020 but increased by >10% from 2020 to 2021. Compared with 2018, 2019, and 2020, the number of claims in the rhinitis symptoms dominant group was significantly decreased in 2021 (p < 0.001, all). In contrast, the number of claims in the eye symptoms dominant group and the rhinitis and eye symptoms dominant group increased in 2021 compared with that in 2018, 2019, and 2020 (p < 0.001, all). Conclusion: Changes in HF treatment and related outcomes could be attributed to lifestyle modifications resulting from the COVID-19 pandemic. Measures, such as limiting outdoor activities and adopting mask-wearing practices may have influenced HF symptoms, preventive behaviors, and the overall approach to treating HF.

DOI： 10.1002/clt2.12394

Scopus

アレルギー領域における診療科・職種横断的リカレント教育の重要性：「出前授業による教育の機会創出事業」参加者データの分析査読有り

正木克宜, 坂下雅文, 小川靖, 猪俣武範, 貝沼圭吾, 神尾敬子, 佐藤さくら, 玉利真由美, 中島沙恵子, 森田英明, 倉島洋介, 二村昌樹, 高橋浩一郎, 春田淳志, 百武美沙, 紋川俊明, 石塚全, 意元義政, 尾山徳孝, 神崎晶, 木戸口正典, 福島敦樹, 福永興壱, 藤枝重治, 安富素子, 足立剛也

アレルギー 73 巻 ( 4 ) 頁： 329 - 339 2024年6月

出版者・発行元：Japanese Journal of Allergology

Background: In the enhancement of allergy care involving multidisciplinary and multiple medical departments, there is a perceived need for education that targets not only specialists but also non-specialists. However, research on the need for and methods of such education remains inadequate. Objective: To design a remote allergy care education program for all medical practitioners and to validate its necessity and utility. Methods: The Empowering Next Generation Allergist/immunologist toward Global Excellence Task Force (ENGAGE-TF), supported by the Japanese Society of Allergology, initiated a virtual educational program called 'Outreach Lectures' in collaboration with Keio University and Fukui University. This initiative was widely promoted through social media and various institutions, and a survey was conducted through its mailing list. Results: 1139 responses were obtained. More than half were physicians from non-allergy specialties, representing a diverse range of healthcare professions. Over 70% expressed being 'very satisfied, ' and over 60% found the difficulty level 'appropriate. ' Free-form feedback revealed differences in learning focus based on profession and learning approach based on years of experience. Conclusion: The high participation rate (90%) of non-specialist physicians underscores the demand for addressing allergic conditions in primary care. The effectiveness of virtual/recurrent education, particularly for healthcare professionals with over 11 years of experience, was implied. Further follow-up investigation focusing on quantitative and objective assessment of educational effectiveness is indispensable.

DOI： 10.15036/arerugi.73.329

Scopus

Updated mutational spectrum and genotype–phenotype correlations in ichthyosis patients with ABCA12 pathogenic variants

Noda T., Takeichi T., Tanahashi K., Ogawa Y., Takeuchi S., Yoshikawa T., Toriyama E., Ashida M., Imakado S., Tsuchihashi H., Okamoto T., Okuno Y., Ogi T., Sugiura K., Kubo A., Muro Y., Suga Y., Ishida-Yamamoto A., Akiyama M.

Experimental Dermatology 33 巻 ( 4 ) 2024年4月

掲載種別：研究論文（学術雑誌）出版者・発行元：Experimental Dermatology

Autosomal recessive congenital ichthyoses (ARCI) is a genetically heterogeneous condition that can be caused by pathogenic variants in at least 12 genes, including ABCA12. ARCI mainly consists of congenital ichthyosiform erythroderma (CIE), lamellar ichthyosis (LI) and harlequin ichthyosis (HI). The objective was to determine previously unreported pathogenic variants in ABCA12 and to update genotype–phenotype correlations for patients with pathogenic ABCA12 variants. Pathogenic variants in ABCA12 were detected using Sanger sequencing or a combination of Sanger sequencing and whole-exome sequencing. To verify the pathogenicity of a previously unreported large deletion and intron variant, cDNA analysis was performed using total RNA extracted from hair roots. Genetic analyses were performed on the patients with CIE, LI, HI and non-congenital ichthyosis with unusual phenotypes (NIUP), and 11 previously unreported ABCA12 variants were identified. Sequencing of cDNA confirmed the aberrant splicing of the variant ABCA12 in the patients with the previously unreported large deletion and intron variant. Our findings expand the phenotype spectrum of ichthyosis patients with ABCA12 pathogenic variants. The present missense variants in ABCA12 are considered to be heterogenous in pathogenicity, and they lead to varying disease severities in patients with ARCI and non-congenital ichthyosis with unusual phenotypes (NIUP).

DOI： 10.1111/exd.15072

Scopus

PubMed

STATE-OF-THE-ART OF GLOBAL START-UP INVESTMENT FOR ALLERGY AND IMMUNOLOGY 2022

Adachi T., Hayano M., Ito Y., Inomata T., Ogawa Y., Kainuma K., Kan-O K., Kurashima Y., Kuwabara Y., Sakashita M., Sato S., Tomita Y., Nakajima S., Futamura M., Masaki K., Tamari M., Ebisawa M., Morita H.

Japanese Journal of Allergology 73 巻 ( 3 ) 頁： 268 - 278 2024年

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Japanese Journal of Allergology

Background: In 2022, the “New Capitalism Grand Design and Implementation Plan” was adopted in Japan, emphasizing the promotion and environmental development of startups. Given this context, an investigation into the startup and investment landscape in the allergy sector, both domestically and internationally, becomes imperative. Methods: We analyzed 156 allergy-related startups from Japan, the US, and Europe from 2010 to 2021. Data on corporate information and investment trends were extracted from databases and VC websites. Results: The total investment reached approximately 7.2 billion USD, with a ratio of 20:6:1 for the US, Europe, and Japan, respectively. The US showed a decline post its peak from 2016-2018, while Europe and Japan experienced growth. Notably, the US primarily invested in biopharmaceuticals for atopic dermatitis and food allergies, Europe in asthma-related apps, and Japan in healthcare apps and cross-border startups. Discussion and conclusion: While Japan's investment environment in the allergy sector remains in its nascent stages and has room for development, the US and Europe are evidently ahead. Considering the rise of startups and funding limitations in Japan, external funding from regions like the US becomes a potential avenue. These findings are anticipated to contribute to the strategic activation of startups in allergy research and development.

DOI： 10.15036/arerugi.73.268

Scopus

PubMed

Impact of COVID‐19 on care‐seeking patterns for hay fever in Japan: A retrospective claims database cohort study 査読有り

Yasutsugu Akasaki, Masao Iwagami, Jaemyoung Sung, Ken Nagino, Takeya Adachi, Hideaki Morita, Mayumi Tamari, Keigo Kainuma, Keiko Kan‐o, Hiroaki Ogata, Masafumi Sakashita, Masaki Futamura, Yosuke Kurashima, Saeko Nakajima, Katsunori Masaki, Yasushi Ogawa, Sakura Sato, Akihiro Miyagawa, Akie Midorikawa‐Inomata, Keiichi Fujimoto, Yuichi Okumura, Kenta Fujio, Tianxiang Huang, Kunihiko Hirosawa, Yuki Morooka, Shintaro Nakao, Akira Murakami, Hiroyuki Kobayashi, Takenori Inomata

Allergy 2023年11月

A case of advanced diffuse large B-cell lymphoma diagnosed from widespread superficial mycosis of the skin 招待有り査読有り

Yuika Suzuki, Chiaki Murase, Yoko Ushijima, Yuriko Hanai, Yasushi Ogawa, Takanori Toyama, Masashi Akiyama

Journal of the European Academy of Dermatology and Venereology : JEADV 2023年

Research impact analysis of international funding agencies in the realm of allergy and immunology 査読有り

Takeya Adachi, Yasushi Ogawa, Tamami Fukushi, Kei Ito, Amane Koizumi, Masashi Shirabe, Masako Toriya, Jun Hirako, Takenori Inomata, Katsunori Masaki, Ryohei Sasano, Sakura Sato, Keigo Kainuma, Masaki Futamura, Keiko Kan-O , Yosuke Kurashima, Saeko Nakajima, Masafumi Sakashita, Hideaki Morita, Aikichi Iwamoto, Sankei Nishima, Mayumi Tamari, Hajime Iizuka

Allergy 2022年5月

Evaluation of adrenaline auto-injector prescription profiles: A population-based, retrospective cohort study within the National Insurance Claims Database of Japan 査読有り

Sakura Sato, Keigo Kainuma, Tatsuya Noda, Motohiro Ebisawa, Masaki Futamura, Tomoaki Imamura, Akihiro Miyagawa, Saeko Nakajima, Yasushi Ogawa, Takenori Inomata, Keiko Kan-O, Yosuke Kurashima, Katsunori Masaki, Tomoya Myojin, Yuichi Nishioka, Masafumi Sakashita, Mayumi Tamari, Hideaki Morita, Takeya Adachi

2022年

More than keratitis, ichthyosis, and deafness: Multisystem effects of lethal GJB2 mutations 査読有り

Lilly E., Bunick C.G., Maley A.M., Zhang S., Spraker M.K., Theos A.J., Vivar K.L., Seminario-Vidal L., Bennett A.E., Sidbury R., Ogawa Y., Akiyama M., Binder B., Hadj-Rabia S., Morotti R.A., Glusac E.J., Choate K.A., Richard G., Milstone L.M.

Journal of the American Academy of Dermatology 80 巻 ( 3 ) 頁： 617 - 625 2019年

掲載種別：研究論文（学術雑誌）出版者・発行元：Journal of the American Academy of Dermatology

Background: Infant death in keratitis-ichthyosis-deafness (KID) syndrome is recognized; its association with specific genotypes and pathophysiology is inadequately understood. Objective: We sought to discover characteristics that account for poor outcomes in lethal KID syndrome. Methods: We collected 4 new cases and 9 previously reported, genotyped cases of lethal KID syndrome. We performed new molecular modeling of the lethal mutants GJB2 p.A88V and GJB2 p.G45E. Results: Infant death occurred in all patients with GJB2 p.G45E and p.A88V; it is unusual with other GJB2 mutations. Early death with those 2 “lethal” mutations is likely multifactorial: during life all had ≥1 serious infection; most had poor weight gain and severe respiratory difficulties; many had additional anatomic abnormalities. Structural modeling of GJB2 p.G45E identified no impact on the salt bridge previously predicted to account for abnormal central carbon dioxide sensing of GJB2 p.A88V. Limitations: This clinical review was retrospective. Conclusion: GJB2 p.G45E and p.A88V are the only KID syndrome mutations associated with uniform early lethality. Those electrophysiologically severe mutations in GJB2 reveal abnormalities in many organs in lethal KID syndrome. All patients with KID syndrome may have subtle abnormalities beyond the eyes, ears, and skin. Early genotyping of KID syndrome births will inform prognostic discussion.

DOI： 10.1016/j.jaad.2018.09.042

Scopus

Survey on patients with undiagnosed diseases in Japan: potential patient numbers benefiting from Japan's initiative on rare and undiagnosed diseases (IRUD). 査読有り

Adachi T, Imanishi N, Ogawa Y, Furusawa Y, Izumida Y, Izumi Y, Suematsu M

Orphanet journal of rare diseases 13 巻 ( 1 ) 頁： 208 2018年

Pigmented macules in Waardenburg syndrome type 2 due to KITLG mutation 査読有り

Ogawa Yasushi, Kono Michihiro, Akiyama Masashi

PIGMENT CELL & MELANOMA RESEARCH 30 巻 ( 5 ) 頁： 501 - 504 2017年

Biallelic Mutations in KDSR Disrupt Ceramide Synthesis and Result in a Spectrum of Keratinization Disorders Associated with Thrombocytopenia 査読有り

Takeichi Takuya, Torrelo Antonio, Lee John Y. W., Ohno Yusuke, Luisa Lozano Maria, Kihara Akio, Liu Lu, Yasuda Yuka, Ishikawa Junko, Murase Takatoshi, Belen Rodrigo Ana, Fernandez-Crehuet Pablo, Toi Yoichiro, Mellerio Jemima, Rivera Jose, Vicente Vicente, Kelsell David P., Nishimura Yutaka, Okuno Yusuke, Kojima Daiei, Ogawa Yasushi, Sugiura Kazumitsu, Simpson Michael A., McLean W. H. Irwin, Akiyama Masashi, McGrath John A.

JOURNAL OF INVESTIGATIVE DERMATOLOGY 137 巻 ( 11 ) 頁： 2344 - 2353 2017年

Image Gallery: Unilaterally dominant acrokeratoelastoidosis (punctate palmoplantar keratoderma type 3) 査読有り

Taki T., Ogawa Y., Sakakibara A., Kono M., Akiyama M.

BRITISH JOURNAL OF DERMATOLOGY 177 巻 ( 4 ) 頁： E157 - E157 2017年

Epstein-Barr Virus-associated Natural Killer/T-cell Lymphoma in a Patient Receiving Therapy with Anti-Tumour Necrosis Factor and Thiopurine 査読有り

Murase Chiaki, Ogawa Yasushi, Yamamoto Azusa, Iriyama Chisako, Akiyama Masashi

ACTA DERMATO-VENEREOLOGICA 97 巻 ( 2 ) 頁： 273 - 274 2017年

抗PM/Scl抗体陽性皮膚筋炎の3例

滝奉樹, 室慶直, 小川靖, 杉浦一充, 秋山真志

日本皮膚科学会雑誌 126 巻 ( 1 ) 頁： 33 - 33 2016年1月

IgE-independent pathophysiology of severe atopic dermatitis demonstrated in an IgE-deficient patient 査読有り

Ogawa, Y., Kono, M., Tsujikawa, M., Tsujiuchi, H., Akiyama, M.

Journal of Dermatological Science 82 巻 ( 2 ) 2016年

Unilateral generalized linear porokeratosis with nail dystrophy 査読有り

Kono, M., Yokoyama, N., Ogawa, Y., Takama, H., Sugiura, K., Akiyama, M.

Journal of Dermatology 43 巻 ( 3 ) 2016年

Non-infectious panniculitis during hydroxyurea therapy in a patient with myeloproliferative disease 査読有り

Ogawa, Y., Akiyama, M.

Acta Dermato-Venereologica 96 巻 ( 4 ) 2016年

Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. 査読有り

Muro Y, Hosono Y, Sugiura K, Ogawa Y, Mimori T, Akiyama M.

Arthritis Res Ther. 17 巻 ( 1 ) 頁： 57 2015年5月

Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis 査読有り

Masaki, S., Kii, I., Sumida, Y., Kato-Sumida, T., Ogawa, Y., Ito, N., Nakamura, M., Sonamoto, R., Kataoka, N., Hosoya, T., Hagiwara, M.

Bioorganic and Medicinal Chemistry 23 巻 ( 15 ) 頁： 4434 - 4441 2015年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：PERGAMON-ELSEVIER SCIENCE LTD

Dysregulation of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) has been demonstrated in several pathological conditions, including Alzheimer's disease and cancer progression. It has been recently reported that a gain of function-mutation in the human DYRK1B gene exacerbates metabolic syndrome by enhancing obesity. In the previous study, we developed an inhibitor of DYRK family kinases (INDY) and demonstrated that INDY suppresses the pathological phenotypes induced by overexpression of DYRK1A or DYRK1B in cellular and animal models. In this study, we designed and synthesized a novel inhibitor of DYRK family kinases based on the crystal structure of the DYRK1A/INDY complex by replacing the phenol group of INDY with dibenzofuran to produce a derivative, named BINDY. This compound exhibited potent and selective inhibitory activity toward DYRK family kinases in an in vitro assay. Furthermore, treatment of 3T3-L1 pre-adipocytes with BINDY hampered adipogenesis by suppressing gene expression of the critical transcription factors PPARc and C/EBPa. This study indicates the possibility of BINDY as a potential drug for metabolic syndrome. (C) 2015 Elsevier Ltd. All rights reserved.

DOI： 10.1016/j.bmc.2015.06.018

Web of Science

Scopus

　前のページ - 次のページ　

<小川 靖>

論文 - 小川 靖

<小川　靖>

論文 - 小川　靖